H.R.6501 - Prescription Drug and Medical Device Price Review Board Act of 2016
12/08/2016
12/22/2016
excessive price
Board
medical devices
days
Cosmetic Act
respect
Federal Food
general
sales
subsection
United States
amendments
respective annual quarter
Effective date
notice of
Medical Device Price Review Board
means
person
manner
effective date
CONGRESS
costs
purposes
Senate
violation of subsection
title
paragraph
violation of section
gt
initial meeting
period
affiliate
opportunity
average price
case
Federal agency
section
Internal Revenue Code
average manufacturer price of
Social Security Act
medical device
enactment
accordance
sale
purpose of conducting research
ENFORCEMENT PROVISIONS
list
Considerations
National Institutes of Health
McDermott
countries
Applicability of certain civil service laws
dosage form
surveys
DEFINITIONS
writing
United States prescription drugs
sufficient data
persons
REPORT
requirements of chapter
response
DeLauro
Kaptur
humans
Formula
dispensing of prescription drugs
December
Welch
Federal agency information necessary
following bill
private agencies
increase
Mails
pharmacy
MEMBERSHIP
Act
IH
ESTABLISHMENT
classification
rebate periods
type of prescription drug
equivalent
Service of process
Government Publishing Office
table of parts
oath
Contract Authority
Development
operation
Civil Penalties
head
maximum annual rate of basic pay payable
level of specificity
continuation
prices of certain prescription drugs
production of evidence
common control
civil contempt
United States district courts
DOC
testimony of witnesses
size
REPORTING REQUIREMENT
effect standards
periodic basis
STAFF
patients
application
difference
Medical Device Profits
extent
subchapter E
Federal Rules of Civil Procedure
Imposition of tax
issue final regulations
Judiciary
Committees
date of enactment
chairperson
additional personnel
disclosure
Director
Initial Meeting
reasonable price
day period
manufacturer
subparagraph
route of administration
Service of subpoenas
ii
provision
Excessive prescription drug
gross sales
excessive prices
Affordable Care Act
regulations
term
safety of prescription drugs
Speaker
pay of
General Schedule pay rates
regulation
Comment Requirement
controls
Beginning
Chapter VIII
Medicaid Rebates
following new subparagraph
jurisdiction
rules
date
report containing
Chairperson
Patent Term
SHORT TITLE
pricing
government
investigation
Administrator of General Services
date of receipt of
following information
reporting period
attendance of witnesses
provisions of title
IMPORTATION
Secretary
MANUFACTURERS
Secretary of Defense
order
Honda
provisions
prescription drugs
Approved Countries
procedures
Assurance of Safety
House of Representatives
similar prescription drug
COMPARABLE PRODUCTS
member
grade GS
d Session
producer
excess
INDIVIDUALS OF PRESCRIPTION DRUGS
Determination of Excessive Price
Power
designee
manufacturers
Continuing Violation
follows
patent owner
issuance
single source drug
Clerical amendment
outside experts
Obtaining Official Data
Schakowsky
Appropriations
Moore
payments
Ways
Doggett
Administrator
conditions
percent greater
Subject
fall
value
earlier violation
prescription drug reimbursement
average manufacturer price
violation
rebate agreements
taxable year
innovator multiple source drug
active ingredient
consideration of
ingredients
development
purposes of clause
annual quarter
Commissioner of Food
CPI increase percentage
standards applicable
final determination
DEVICES
trade secret
civil penalty
approved country
country
importer
Medicare
making payments
Patient Protection
years
designated place of hearing
preceding calendar year
administrative support services necessary
judicial district
Confidentiality
total Federal investment
appropriate committees of Congress
place
Energy
PROHIBITION
activities
recommendations
Federal law
confidential information
facts
Organization
Failure
business
governing appointments
EXCESSIVE PRESCRIPTION DRUG
end of
reimbursable basis
strength
Federal agencies
matter
competitive service
Medical Device Price Review
therapeutic class
Review Board
FEDERAL AGENCIES
quarters
formula
true cost of production
HOUSE OF REPRESENTATIVES December
statement
Affordable Drugs
Assistance
lt
fields of consumer advocacy
Determination of
United States of America
Excess Prescription Drug
Administration
factors determinative
Secretary of Veterans Affairs
medicine
pharmacology
following new section
following new item
request
Investigations
preceding year
Means
Medicaid Services
Centers
dispensing
Commerce
Petitions
circumstances
initiative
patient population
entity
duties
Code
subchapter III of chapter
